GlassScriptPhysician profile
Brandon T Marion
NPI 1124384888
$11,997.12
in general payments reported to CMS, 2019-2025
34 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,644 · 2020: $416 · 2021: $1,124 · 2022: $1,810 · 2023: $1,986 · 2024: $1,269 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,002.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,137.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,497.97 | 2019-2025 | Xifaxan, Trulance |
| Covidien LP | $1,460.09 | 2019 | |
| Janssen Biotech, INC. | $1,275.37 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $869.06 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Endogastric Solutions, INC | $817.10 | 2019 | |
| Celgene Corporation | $395.74 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $353.14 | 2020-2024 | Linzess |
| Ardelyx, INC. | $336.39 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $332.14 | 2019-2025 | Injectafer |
| Gilead Sciences, INC. | $267.30 | 2019-2023 | |
| Lilly USA, LLC | $257.61 | 2024-2025 | Omvoh, Zepbound |
| Aimmune Therapeutics, INC. | $243.04 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $224.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $216.79 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $185.10 | 2019-2024 | Ocaliva |
| Braintree Laboratories, INC. | $134.53 | 2019-2024 | Suflave, Sutab |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $110.09 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $87.64 | 2021-2023 | |
| Pfizer INC. | $86.98 | 2019-2025 | |
| Boston Scientific Corporation | $77.15 | 2021-2023 | Orcapod |
| Novo Nordisk INC | $76.27 | 2019-2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $66.77 | 2024-2025 | Voquezna |
| Genzyme Corporation | $60.31 | 2023-2025 | |
| Organon LLC | $54.36 | 2023-2024 | Hadlima, Renflexis |
| E.R. Squibb & Sons, L.L.C. | $52.82 | 2021 | |
| Merck Sharp & Dohme LLC | $37.66 | 2021-2024 | Dificid |
| Qol Medical, LLC | $37.04 | 2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $34.24 | 2024-2025 | Dupixent |
| Ucb, INC. | $32.40 | 2019 | |
| Shire North American Group INC | $31.49 | 2019 | |
| Celltrion USA INC. | $23.70 | 2025 | Vegzelma |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Marion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.